Progress in the application of biologics in allergen specific immunotherapy
10.3760/cma.j.cn112150-20241125-00944
- VernacularTitle:生物制剂在过敏原特异性免疫治疗中的应用进展
- Author:
Xing YANG
1
;
Minghui YU
;
Lu ZHANG
;
Wenqi CHE
;
Huanping ZHANG
Author Information
1. 山西医科大学第三医院（山西白求恩医院 山西医学科学院 同济山西医院）过敏反应科，太原 030032
- Publication Type:Journal Article
- Keywords:
Allergic diseases;
Allergen specific immunotherapy;
Biologics
- From:
Chinese Journal of Preventive Medicine
2025;59(10):1770-1778
- CountryChina
- Language:Chinese
-
Abstract:
The prevalence of allergic diseases is on the rise,posing a significant global health challenge.Allergen specific immunotherapy(AIT)is the only treatment capable of altering the natural course of allergic diseases,offering long-term efficacy and the potential to prevent disease progression.However,its widespread application is hindered by factors such as lengthy treatment duration,adverse reactions,and patient compliance issues.In recent years,biologics targeting type 2 inflammatory pathways have played a crucial role at various stages of different allergic diseases.Research indicates that for patients with moderate to severe allergic diseases,using biologics during or prior to AIT can significantly enhance the safety of AIT,reduce the time required to reach maintenance doses,and markedly improve symptom scores.This article elucidates the synergistic mechanisms and recent advancements in the combined application of biologics and AIT in the treatment of allergic diseases.The aim is to provide a reference for the standardized treatment of allergic diseases.
